(Adnkronos) - “Da oltre 30 anni cerchiamo di portare risposte a chi è colpito da malattie rare cercano di sviluppare farmaci altamente efficaci. Abbiamo messo a disposizione della popolazione italiana molecole che hanno trasformato la storia di queste patologie”. Ad affermarlo è stata Anna Chiara Rossi, Vice President & General Manager Italy di Alexion, a margine della presentazione di uno studio di Thje European House Ambrosetti.
Category
🗞
NewsTranscript
00:00It is estimated that about 3 million people in Italy are affected by a rare disease.
00:12These are diseases that have a devastating impact on those who are affected and on their families,
00:18because we often talk about diseases that are highly disabling and potentially deadly.
00:25From here, our commitment, which has been explicit for over 30 years.
00:32For over 30 years, at Alexio, we have focused on trying to bring answers
00:38and transform the lives of these patients and their families,
00:42first of all by trying to develop highly effective and transformative drugs.
00:48In fact, over the years, we have been able, in different situations, to succeed in this regard.
00:54In fact, today we have made available to the Italian population five molecules for seven indications.
01:01Molecules that have undoubtedly managed to transform the natural history of these pathologies.
01:08Our commitment does not stop here.
01:10We continue to invest because we believe that it is our duty to contribute
01:16to trying to debell these conditions.
01:24www.alexio.com